Background/Objective: The post‐intensive care unit (ICU) period significantly impacts patients’ overall well‐being, raising concerns among patients, families, healthcare professionals, and decision‐makers. This study aims to evaluate 1‐year survival rates, return to work, and daily functionality of individuals discharged from the ICU. Materials and Methods: A retrospective analysis was conducted in a medical ICU, focusing on patients with a minimum 48‐h ICU stay who were subsequently discharged from the hospital. Results: The study included 154 patients with a median age of 51 (IQR: 34–68) years, of whom 79 (51%) were male. The 1‐year mortality rate was 23.4%. Within the first year, rehospitalization occurred in 54.5%, and ICU readmission was observed in 20.1%. Notably, 89.8% of the patients were able to perform self‐care activities, such as toileting and dressing. However, 63.6% of the patients had not returned to work within the first year. A comparison between patients requiring critical interventions and those who did not revealed a return‐to‐work rate of 21.4% for the former and 50% for the latter ( p = 0.002). Conclusion: The findings indicate that approximately one‐quarter of patients treated in intensive care and discharged from the hospital died within 1 year. While a significant proportion (90%) could independently manage self‐care tasks, the majority experienced delays in returning to work. These findings highlight the need for enhanced post‐ICU care to improve patient outcomes.
Objectives: To determine the demographic and clinical characteristics, potential specific antidote treatments, clinical outcomes, and organ failure (morbidity) rates of patients with mushroom poisoning admitted to our center. Methods: We included 425 patients admitted to the emergency department of Kayseri City Hospital complaining of mushroom poisoning, between May 2018 and December 2023, who met the study criteria. Results: The median age of the 425 patients admitted was 51 years (34–63); 49.5% were female (n = 211), and 75% (n = 319) were admitted by ambulance. According to the Poisoning Severity Score, 70.3% (n = 299) of cases were mild, 21.9% (n = 93) moderate, 7.3% (n = 31) severe, and 0.5% (n = 2) fatal. Patients who received specific antidote treatment had a statistically significantly higher morbidity rate than those who did not (48.6% vs. 22.9%, p < 0.01). In the subgroup analysis, hepatotoxicity was more common (35.8% vs. 8.8%, p < 0.01), whereas there was no significant difference in other organ failure. Conclusion: Mushroom poisoning is an uncommon type of poisoning that varies seasonally. The integrity of treatment may have been lost because of intermittent visits. We recommend careful evaluation of the patients and rapid initiation of specific possible antidote therapies, in addition to basic supportive treatment (fluid resuscitation, activated charcoal, and so on).
Background/Objectives: Elevated Procalcitonin (PCT) levels are frequently encountered in clinical practice but may occur in both infectious and non-infectious conditions, making their interpretation challenging. This study evaluated the diagnostic performance of PCT, CRP, and lactate for differentiating sepsis, infectious conditions, and non-infectious conditions in patients with elevated baseline PCT levels. Methods: In this single-center retrospective observational study, 1072 adults presenting to the ED between June and December 2024 with serum PCT ≥ 0.51 ng/mL were included. Patients were classified into sepsis (n = 272), infection (n = 618), and non-infection (n = 182) groups according to the Sepsis-3 criteria and comprehensive clinical adjudication. ROC analyses and DeLong tests were performed to evaluate biomarker performance. Results: For identifying sepsis, PCT demonstrated better discriminatory performance (AUC 0.683) than CRP (AUC 0.619) and lactate (AUC 0.620), with significant differences between PCT and both CRP (p = 0.009) and lactate (p = 0.018). The optimal PCT cut-off was 2.35 ng/mL (sensitivity 65.8%, specificity 59.5%). For differentiating infectious from non-infectious conditions, CRP showed modest discrimination (AUC 0.640), whereas PCT (AUC 0.581) and lactate (AUC 0.439) performed poorly. Lactate showed the highest prognostic performance for in-hospital mortality (AUC 0.598), although overall prognostic accuracy remained limited. Conclusions: In ED patients with elevated baseline PCT levels, PCT showed better discrimination for sepsis than CRP and lactate, whereas CRP performed modestly in differentiating infectious from non-infectious conditions. None of the biomarkers demonstrated sufficient accuracy for standalone clinical use, supporting their role as complementary tools alongside comprehensive clinical assessment and the Sepsis-3 criteria.
Background: The Sequential Organ Failure Assessment (SOFA) score has been widely used for nearly three decades to evaluate organ dysfunction and predict mortality in patients with sepsis. Advances in critical care practice have led to the development of an updated version, SOFA-2, incorporating contemporary organ support strategies and revised clinical thresholds. However, real-world comparative data evaluating the prognostic performance of the original SOFA score (SOFA-1) and SOFA-2 remain limited. This study aimed to compare the prognostic performance of SOFA-1 and SOFA-2 for predicting ICU, 28-day, and 90-day mortality in patients with sepsis. Methods: This retrospective, single-center observational cohort study included adult patients (≥ 18 years) diagnosed with sepsis according to Sepsis-3 criteria and admitted between December 2023 and August 2024. SOFA-1 and SOFA-2 scores were calculated using clinical and laboratory data obtained at ICU admission. The primary outcome was ICU mortality; secondary outcomes were 28-day and 90-day mortality. Multivariable logistic regression was performed to identify independent predictors of mortality. Discriminatory performance was assessed using receiver operating characteristic analysis, and areas under the curve were compared using DeLong’s test. Optimal cut-off values were determined using the Youden index. Results: Among 417 screened patients, 222 met the inclusion criteria. ICU mortality was 57.7%. Each one-point increase in SOFA-1 and SOFA-2 scores was associated with a 42% and 43% increase in ICU mortality, respectively ( p < 0.001 for both). The area under the curve for ICU mortality prediction was 0.843 (95% CI 0.792–0.895) for SOFA-1 and 0.845 (95% CI 0.795–0.896) for SOFA-2; the difference between the two scores was not statistically significant ( p = 0.79). SOFA-2 demonstrated slightly higher specificity, whereas SOFA-1 showed marginally higher sensitivity at the optimal cut-off value. Conclusions: SOFA-1 and SOFA-2 demonstrated good discriminatory performance for predicting ICU mortality in this cohort. Although no statistically significant difference was observed between the two scoring systems, larger prospective multicenter studies are needed to determine whether clinically meaningful differences exist and to further evaluate the potential advantages of SOFA-2. Trial registration: Not applicable.
Background: Treatment strategies for myelodysplastic syndromes (MDS) range from supportive care to disease-modifying therapies, depending on risk stratification and patient characteristics. Hypomethylating agents (HMAs) remain the standard treatment for higher-risk disease, whereas allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative option. This study evaluated real-world survival outcomes and prognostic factors in patients with MDS treated with HMAs or allo-HSCT. Methods: A total of 79 patients with MDS who received azacitidine, decitabine, or allo-HSCT were retrospectively analyzed. Overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards analyses. To address potential immortal time bias, a prespecified 6-month landmark analysis was additionally performed. Results: Median OS was 14.9 months (95% CI, 9.9–20.0) with azacitidine, 10.0 months (95% CI, 6.8–13.2) with decitabine, and 48.0 months (95% CI, 19.9–76.1) after allo-HSCT. Patients undergoing allo-HSCT were significantly younger and had better ECOG performance status than those receiving HMAs. After adjustment for age, ECOG performance status, and IPSS-R risk category, treatment modality remained significantly associated with OS in the multivariable Cox regression model. In the prespecified 6-month landmark analysis, the survival advantage associated with allo-HSCT remained significant, although the adjusted association was attenuated. Conclusions: In this real-world cohort of actively treated patients with MDS, allo-HSCT was associated with longer overall survival than HMAs. Although this association persisted after adjustment for major clinical confounders and in a landmark analysis addressing immortal time bias, residual confounding related to treatment selection cannot be excluded. These findings should therefore be interpreted as an association rather than evidence of a causal treatment effect.
Background/Objectives: Thrombocytopenia (TP) is common in critically ill patients, but the significance of its severity, timing, persistence, and admission subthreshold platelet count (PC) remains uncertain. We evaluated these associations with mortality in a medical ICU. Methods: In this prospective cohort study, 280 adults admitted to a tertiary medical ICU (September 2023–August 2024) were followed until ICU discharge or death. TP was defined as a PC < 150 × 109/L, and admission STP as a first ICU PC of 150–199 × 109/L, irrespective of later platelet course. Outcomes included mortality (ICU, hospital, 28-day, 90-day), organ support, and major complications. Results: TP occurred in 118 patients (42.1%), with higher crude mortality at all time points (all p < 0.001). In the lagged time-dependent Cox analysis, ICU-acquired TP was associated with ICU mortality in the minimally adjusted model (HR 1.93, CI 1.12–3.35; p = 0.018) but not after adjustment for invasive MV (aHR 1.31, CI 0.72–2.40; p = 0.372). Admission TP was not significantly associated with ICU mortality in the adjusted model (aHR 1.22, CI 0.74–2.00; p = 0.436). Admission PC showed limited discrimination (AUC 0.583, CI 0.508–0.657). No statistically significant difference was found between admission STP and PC ≥ 200 × 109/L (exploratory comparison, wide CIs). Conclusions: TP was associated with disease severity and worse crude outcomes, but adjusted longitudinal analyses did not establish an independent association with ICU mortality. No statistically significant difference was found for admission STP versus PC ≥ 200 × 109/L in this exploratory comparison; this should not be interpreted as clinical equivalence or as indicating no prognostic value.